---
title: "Cybin publishes corporate presentation on HLP003, deuterated serotonergic agonist for major depressive disorder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291144849.md"
description: "Cybin published a corporate presentation highlighting Phase 3 dosing for HLP003, a deuterated serotonergic agonist for major depressive disorder, which holds FDA Breakthrough Therapy Designation. Topline data from the APPROACH trial is expected in Q4 2026. Additionally, HLP004 for generalized anxiety disorder has completed Phase 2 signal-finding. The company reported a cash position of US$ 157.3 million as of March 31, 2026, following a US$ 50 million offering in June 2026, and cited an IP portfolio of over 350 filed patents."
datetime: "2026-06-29T12:23:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291144849.md)
  - [en](https://longbridge.com/en/news/291144849.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291144849.md)
generator: "portal-rs"
---

# Cybin publishes corporate presentation on HLP003, deuterated serotonergic agonist for major depressive disorder

-   Cybin outlined Phase 3 dosing underway for HLP003 in adjunctive major depressive disorder; FDA Breakthrough Therapy Designation highlighted. \* Phase 3 APPROACH topline data targeted for Q4 2026; HLP004 positioned in generalized anxiety disorder with Phase 2 signal-finding complete. \* Cash position of US$ 157.3 million as of March 31, 2026; completed a US$ 50 million underwritten offering in June 2026. \* IP portfolio cited at over 350 filed patents with over 100 granted; issued patents framed as providing protection until at least 2041. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Cybin announces annual general and special shareholder meeting](https://longbridge.com/en/news/296336431.md)
- [Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety](https://longbridge.com/en/news/294701596.md)
- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)
- [ADM announces Q3 2026 distribution of R$ 0.22 per unit, payable Sept. 15](https://longbridge.com/en/news/296399586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**